Clinical Trials Directory

Trials / Completed

CompletedNCT01732614

Topcon Endpoint Management

Safety Assessment and Therapeutic Effect of Non-damaging Patterned Scanning Laser Phototherapy in Patients With Diffuse Diabetic Macular Edema

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
10 (actual)
Sponsor
Retinal Consultants of Arizona · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This trial seeks to prove that sub-lethal laser power levels are as effective and less damaging than traditional laser. Diabetic macular edema (DME) affects approximately 29% of diabetic patients with a disease duration of 20 or more years and is one of the most frequent causes of vision loss in this population. The Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated a significant benefit of laser photocoagulation for the treatment of clinically significant macular edema, reducing the incidence of vision loss by approximately 50% at 3 years' follow-up.

Detailed description

Sub-visible, non-damaging visible laser (532 nm) exposures of 100 ms in duration resulted in enhanced expression of heat shock proteins in the retina. To test clinical efficacy of sub-visible retinal therapy using ms-range exposures of visible lasers one needs first to establish proper titration methods necessary to assure on one hand the lack of tissue damage, and on the other hand sufficient hyperthermia to elicit cellular response.

Conditions

Interventions

TypeNameDescription
PROCEDURETopcon Endpoint Management laser

Timeline

Start date
2012-08-01
Primary completion
2013-11-01
Completion
2013-12-01
First posted
2012-11-26
Last updated
2014-03-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01732614. Inclusion in this directory is not an endorsement.